Bergenstal, Richard M., MD, Executive Director, International Diabetes Center 1983 -

Carlson, Anders L., MD, Medical Director, International Diabetes Center 2015 -

Criego, Amy B., MD, MS, Medical Director of International Diabetes Center

Johnson, Mary L. , Director, Administration and Clinical Research

Martens, Thomas W., MD, FACP, Medical Director, International Diabetes Center 2015 -

Simonson, G. D., Director, Care Transformation & Training

Willis, Holly J., Research Investigator

-cell function over time on glycemic outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): differential treatment effects of dual therapy. 

Diabetes care. 2024

A comparison of continuous glucose monitoring-measured time-in-range 70-180 mg/dL versus time-in-tight-range 70-140 mg/dL. 

Diabetes Technology & Therapeutics. 2024

A scalable application of artificial intelligence-driven insulin titration program to transform type 2 diabetes management. 

Diabetes Technology & Therapeutics. 2024

Continuous glucose monitoring metrics and hemoglobin A1c relationship in patients with type 2 diabetes treated by hemodialysis. 

Diabetes Technology & Therapeutics. 2024

Continuous glucose monitoring prediction of gestational diabetes mellitus and perinatal complications. 

Diabetes Technology & Therapeutics. 2024

Continuous glucose monitoring profiles in pregnancies with and without gestational diabetes mellitus. 

Diabetes care. 2024

Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1. 

The lancet. Diabetes & endocrinology. 2024

Continuous glucose monitoring-derived differences in pregnancies with and without adverse perinatal outcomes. 

Obstetrics and Gynecology. 2024

Control-IQ technology use in individuals with high insulin requirements: results from the Multicenter Higher-IQ Trial. 

Journal of Diabetes Science and Technology. 2024

Expert panel recommendations for a standardized ambulatory glucose profile report for connected insulin pens. 

Diabetes Technology & Therapeutics. 2024

Frequency and severity of hypoglycemia under conditions of increased hypoglycemic risk with insulin efsitora alfa versus insulin glargine treatment in participants with type 2 diabetes. 

Diabetes Therapy. 2024

Glucose levels measured with continuous glucose monitoring in uncomplicated pregnancies. 

BMJ open diabetes research & care. 2024

Glycemic outcomes persist for up to 2 years in very young children with the Omnipod(®) 5 Automated Insulin Delivery System. 

Diabetes Technology & Therapeutics. 2024

Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. 

Diabetes, Obesity & Metabolism. 2024

Increase access, reduce disparities: recommendations for modifying medicaid CGM coverage eligibility criteria. 

Journal of Diabetes Science and Technology. 2024

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. 

Lancet (London, England). 2024

Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. 

Diabetes, Obesity & Metabolism. 2024

Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. 

Lancet Reg Health Am. 2024

Severe hypoglycemia and impaired awareness of hypoglycemia persist in people with type 1 diabetes despite use of diabetes technology: results from a cross-sectional survey. 

Diabetes care. 2024

The Diabetes Technology Society error grid and trend accuracy matrix for glucose monitors. 

Journal of Diabetes Science and Technology. 2024

The use of rescue insulin in the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). 

Diabetes care. 2024

Time in range, time in tight range, and average glucose relationships are modulated by glycemic variability: identification of a glucose distribution model connecting glycemic parameters using real-world data. 

Diabetes Technology & Therapeutics. 2024

Two years with a tubeless automated insulin delivery system: a single-arm multicenter trial in children, adolescents, and adults with Type 1 diabetes. 

Diabetes Technology & Therapeutics. 2024

Unleashing the potential of blood glucose monitoring data with the Ambulatory Glucose Profile Report. 

Clinical Diabetes. 2024

A comparison of continuous glucose monitoring estimated hemoglobin A1c in adults with type 1 or type 2 diabetes. 

Diabetes Technology & Therapeutics. 2023

A roadmap to an equitable digital diabetes ecosystem. 

Endocrine Practice. 2023

Advancing diabetes quality measurement in the era of continuous glucose monitoring. 

Sci Diabetes Self Manag Care. 2023

Assessing time in range with postprandial glucose-focused titration of ultra rapid lispro (URLi) in people with type 1 diabetes. 

Diabetes Therapy. 2023

Assessment of the glucose management indicator using different sampling durations. 

Diabetes Technology & Therapeutics. 2023

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. 

Cardiovascular Diabetology. 2023

Comprehensive telehealth model to support diabetes self-management. 

JAMA network open. 2023

Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. 

Endocrine Reviews. 2023

Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: the head-to-head randomized controlled InRange trial. 

Diabetes, Obesity & Metabolism. 2023

Correlation between time in range and HbA1c in people with type 2 diabetes on basal insulin: post hoc analysis of the SWITCH PRO study. 

Diabetes Therapy. 2023

Discordance between glucose management indicator and glycated hemoglobin in people without diabetes. 

Diabetes Technology & Therapeutics. 2023

Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: a national retrospective observational cohort study. 

Diabetes, Obesity & Metabolism. 2023

Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. 

Diabetes Technology & Therapeutics. 2023

Increased derived time in range is associated with reduced risk of major adverse cardiovascular events, severe hypoglycemia, and microvascular events in type 2 diabetes: a post hoc analysis of DEVOTE. 

Diabetes Technology & Therapeutics. 2023

Roadmap to the effective use of continuous glucose monitoring in primary care. 

Diabetes Spectrum. 2023

Roadmap to the effective use of continuous glucose monitoring: innovation, investigation, and implementation. 

Diabetes Spectrum. 2023

Roadmaps to continuous glucose monitoring's role in transforming diabetes management. 

Diabetes Spectrum. 2023

Safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. 

Diabetes care. 2023

Safety and glycemic outcomes during the MiniMed(TM) advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2023

The relationship between percent time <70 mg/dL and percent time <54 mg/dL measured by continuous glucose monitoring. 

Diabetes Technology & Therapeutics. 2023

A comparison of postprandial glucose control in the Medtronic advanced hybrid closed-loop system versus 670G. 

Diabetes Technology & Therapeutics. 2022

A safe and simple algorithm for adding and adjusting mealtime insulin to basal-only therapy. 

Clinical Diabetes. 2022

Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2022

Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. 

Journal of Diabetes Science and Technology. 2022

Continuous glucose monitoring in adults with type 1 diabetes with 35 years duration from the DCCT/EDIC Study. 

Diabetes care. 2022

Continuous ketone monitoring consensus report 2021. 

Journal of Diabetes Science and Technology. 2022

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. 

The lancet. Diabetes & endocrinology. 2022

How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: findings from the first investigation with the Omnipod® 5 System. 

Diabetes Research and Clinical Practice. 2022

How use of continuous glucose monitoring can address therapeutic inertia in primary care. 

Postgraduate Medicine. 2022

Impact of temporary glycemic target use in the hybrid and advanced hybrid closed-loop systems. 

Diabetes Technology & Therapeutics. 2022

Interindividual variability in average glucose-glycated haemoglobin relationship in type 1 diabetes and implications for clinical practice. 

Diabetes, Obesity & Metabolism. 2022

Islet autoimmunity is highly prevalent and associated with diminished β-cell function in patients with type 2 diabetes in the Grade Study. 

Diabetes. 2022

Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes. 

Journal of Diabetes and Its Complications. 2022

Real-world evidence supporting Tandem Control-IQ Hybrid Closed-Loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations. 

Diabetes Technology & Therapeutics. 2022

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. 

Cardiovascular Diabetology. 2022

Safety and glycemic outcomes during the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in adolescents and adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2022

Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. 

Diabetes care. 2022

Symptomatic diabetic autonomic neuropathy in type 1 diabetes (T1D): findings from the T1D exchange. 

Journal of Diabetes and Its Complications. 2022

The optimal duration of a run-in period to initiate continuous glucose monitoring for a randomized trial. 

Diabetes Technology & Therapeutics. 2022

A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. 

Lancet (London, England). 2021

Acacia gum is well tolerated while increasing satiety and lowering peak blood glucose response in healthy human subjects. 

Nutrients. 2021

Addressing shortfalls of laboratory HbA(1c) using a model that incorporates red cell lifespan. 

eLife. 2021

Beyond A1C-standardization of continuous glucose monitoring reporting: why it is needed and how it continues to evolve. 

Diabetes Spectrum. 2021

Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. 

PloS One. 2021

Continuous glucose monitoring and glycemic control in patients with type 2 diabetes treated with basal insulin-reply. 

JAMA. 2021

Continuous glucose monitoring integration for remote diabetes management: virtual diabetes care with case studies. 

Diabetes Technology & Therapeutics. 2021

Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. 

JAMA. 2021

Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. 

Diabetes, Obesity & Metabolism. 2021

Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care. 

Journal of Diabetes Science and Technology. 2021

First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2021

Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. 

Journal of the Endocrine Society. 2021

Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. 

Diabetologia. 2021

Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data. 

Diabetes, Obesity & Metabolism. 2021

Hypoglycemia and glycemic control in older adults with type 1 diabetes: baseline results from the WISDM Study. 

Journal of Diabetes Science and Technology. 2021

Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system. 

Diabetes Research and Clinical Practice. 2021

Initiating insulin in the emergency center and urgent care to prevent hospital admission for patients with hyperglycemia: a unique insulin starter kit. 

Journal of Diabetes Science and Technology. 2021

Lived experience of advanced hybrid closed-loop versus hybrid closed-loop: patient-reported outcomes and perspectives. 

Diabetes Technology & Therapeutics. 2021

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. 

Diabetes, Obesity & Metabolism. 2021

Lost in translation: a disconnect between the science and Medicare coverage criteria for continuous subcutaneous insulin infusion. 

Diabetes Technology & Therapeutics. 2021

Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C). 

Postgraduate Medicine. 2021

Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. 

Diabetes care. 2021

Real-world, patient-reported and clinic data from individuals with type 1 diabetes using the MiniMed 670G hybrid closed-loop system. 

Diabetes Technology & Therapeutics. 2021

Remote application and use of real-time continuous glucose monitoring by adults with type 2 diabetes in a virtual diabetes clinic. 

Diabetes Technology & Therapeutics. 2021

Renal complications and duration of diabetes: an international comparison in persons with type 1 diabetes. 

Diabetes Therapy. 2021

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. 

Diabetes care. 2021

The digital/virtual diabetes clinic: the future Is now-recommendations from an international panel on diabetes digital technologies introduction. 

Diabetes Technology & Therapeutics. 2021

The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. 

Diabetes care. 2021

Trial of a new diabetes education model: closing the gap in health disparity for people with diabetes. 

Journal of Diabetes Science and Technology. 2021

Ultrarapid lispro demonstrates similar time in target range to lispro with a hybrid closed-loop system. 

Diabetes Technology & Therapeutics. 2021

Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. 

Diabetologia. 2020

Diabetes telehealth solutions: improving self-management through remote initiation of continuous glucose monitoring. 

Journal of the Endocrine Society. 2020

Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. 

JAMA. 2020

Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. 

JAMA. 2020

Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). 

Pediatric Diabetes. 2020

Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). 

Diabetologia. 2020

InRange: comparison of the second-generation basal insulin analogues glargine 300 U/mL and degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring-study design. 

Diabetes Therapy. 2020

International Diabetes Center: COVID-19 won't stop us from fulfilling our mission. 

Journal of Diabetes Science and Technology. 2020

Ultra-rapid lispro improves postprandial glucose control and time in range in type 1 diabetes compared to lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy. 

Diabetes Technology & Therapeutics. 2020

Use of a diabetes-specific nutritional shake to replace a daily breakfast and afternoon snack improves glycemic responses assessed by continuous glucose monitoring in people with type 2 diabetes: a randomized clinical pilot study. 

BMJ open diabetes research & care. 2020

. 2018;41:2275-2280. 

Diabetes care. 2019

Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. 

Lancet (London, England). 2019

Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study. 

Journal of Clinical Endocrinology and Metabolism. 2019

Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: a multicentre, randomized controlled trial using continuous glucose monitoring. 

Diabetes, Obesity & Metabolism. 2019

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. 

Age and Ageing. 2019

Emphasizing optimal diabetes management for all races/ethnicities, but not race/ethnicity-specific cut points for hemoglobin A1c. 

JAMA ophthalmology. 2019

Evaluation of insulin glargine and exenatide alone and in combination: a randomized clinical trial with continuous glucose monitoring and ambulatory glucose profile analysis. 

Endocrine Practice. 2019

Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. 

Journal of Diabetes and Its Complications. 2019

Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. 

Diabetes Technology & Therapeutics. 2019

Insulin dosing guidance to optimise type 2 diabetes management - authors' reply. 

Lancet (London, England). 2019

Rationale and design for a GRADE substudy of continuous glucose monitoring. 

Diabetes Technology & Therapeutics. 2019

State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. 

Diabetes Technology & Therapeutics. 2019

The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. 

Diabetes Technology & Therapeutics. 2019

The relationships between time in range, hyperglycemia metrics, and HbA1c. 

Journal of Diabetes Science and Technology. 2019

Validation of time in range as an outcome measure for diabetes clinical trials. 

Diabetes care. 2019

Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. 

Diabetes care. 2019

Alogliptin in patients with type 2 diabetes receiving metformin and sulfonylurea therapies in the EXAMINE Trial. 

American Journal of Medicine. 2018

Average clinician-measured blood pressures and cardiovascular outcomes in patients with type 2 diabetes mellitus and ischemic heart disease in the EXAMINE Trial. 

Journal of the American Heart Association. 2018

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. 

Lancet (London, England). 2018

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial. 

Diabetes, Obesity & Metabolism. 2018

Glucose Management Indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. 

Diabetes care. 2018

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). 

Diabetes, Obesity & Metabolism. 2018

High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. 

Diabetes, Obesity & Metabolism. 2018

Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. 

Diabetes Technology & Therapeutics. 2018

Time savings using a standardized glucose reporting system and ambulatory glucose profile. 

Journal of Diabetes Science and Technology. 2018

Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. 

Clinical Cardiology. 2018

2017;40:777-83. 

Diabetes care. 2017

Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. 

BMJ open. 2017

Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the Diabetes Control and Complications Trial. 

Diabetes care. 2017

Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. 

Diabetes care. 2017

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. 

Diabetes, Obesity & Metabolism. 2017

Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. 

Annals of Internal Medicine. 2017

Digital health care by in silico glycation of HbA1 blood cells. 

Journal of Diabetes Science and Technology. 2017

Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: an analysis using continuous glucose monitoring. 

Diabetes/Metabolism Research and Reviews. 2017

Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND Randomized Clinical Trial. 

JAMA. 2017

Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. 

The lancet. Diabetes & endocrinology. 2017

Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). 

Diabetes care. 2017

Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2017

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naive people with type 2 diabetes: 12-month results from the EDITION 3 trial. 

Diabetes and Metabolism. 2017

Identifying trends in undiagnosed diabetes in U.S. adults by using a confirmatory definition: a cross-sectional study. 

Annals of Internal Medicine. 2017

Liraglutide and renal outcomes in type 2 diabetes. 

New England Journal of Medicine. 2017

REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. 

Diabetes care. 2017

Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. 

Annals of Internal Medicine. 2017

Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. 

Diabetes, Obesity & Metabolism. 2017

The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. 

Diabetes care. 2017

The hybrid closed loop therapy system: a step closer to an artificial pancreas. 

Minn Physician. 2017

Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl peptidase 4 inhibitor alogliptin. 

Hypertension (Dallas, Tex.. 2016

Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE Trial. 

Diabetes care. 2016

Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. 

Diabetes care. 2016

Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. 

Diabetes Technology & Therapeutics. 2016

Hospital insulin protocol aims for glucose control in glucocorticoid-induced hyperglycemia. 

Endocrine Practice. 2016

Hypoglycemia in older adults with type 1 diabetes. 

Diabetes Technology & Therapeutics. 2016

Liraglutide and cardiovascular outcomes in type 2 diabetes. 

New England Journal of Medicine. 2016

Racial differences in and prognostic value of biomarkers of hyperglycemia. 

Diabetes care. 2016

Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. 

Diabetes, Obesity & Metabolism. 2016

Recurrent endocrine cycles. 

Journal of Diabetes Science and Technology. 2016

Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes. 

Journal of Diabetes. 2016

Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. 

Diabetes care. 2016

Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. 

JAMA. 2016

The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. 

American Journal of Respiratory and Critical Care Medicine. 2016

Clinical utility of SMBG: recommendations on the use and reporting of SMBG in clinical research. 

Diabetes care. 2015

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange Clinic registry. 

Diabetes care. 2015

Design of FLAT-SUGAR: randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes. 

Diabetes care. 2015

Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. 

JAMA. 2015

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. 

Diabetes, Obesity & Metabolism. 2015

Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers!. 

Diabetes care. 2015

Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. 

BMJ open diabetes research & care. 2015

Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. 

Diabetologia. 2015

Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. 

Diabetes care. 2015

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. 

Diabetes, Obesity & Metabolism. 2015

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. 

Diabetologia. 2015

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. 

Diabetes care. 2015

Multicenter observational study of the first-generation intravenous blood glucose monitoring system in hospitalized patients. 

Journal of Diabetes Science and Technology. 2015

New insulin Glargine 300 Units/mL versus Glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). 

Diabetes care. 2015

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). 

Diabetes, Obesity & Metabolism. 2015

Predictors of hypoglycemia in the ASPIRE In-Home study and effects of automatic suspension of insulin delivery. 

Journal of Diabetes Science and Technology. 2015

Response to comment on Wong et al. Real-time continuous glucose monitoring among participants in the T1D exchange clinic registry. 

Diabetes care. 2015

Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. 

Mayo Clinic Proceedings. 2015

Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a randomized controlled trial. 

Canadian journal of diabetes. 2015

A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with type 2 diabetes

2014

Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. 

Journal of Diabetes Science and Technology. 2014

Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. 

Diabetes, Obesity & Metabolism. 2014

Depression in adults in the T1D Exchange Clinic Registry. 

Diabetes care. 2014

Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. 

Diabetologia. 2014

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. 

Pancreas. 2014

Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. 

Diabetes care. 2014

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). 

Diabetes care. 2014

Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. 

Diabetes care. 2014

ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. 

Journal of Diabetes Science and Technology. 2013

Alogliptin after acute coronary syndrome in patients with type 2 diabetes. 

New England Journal of Medicine. 2013

Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. 

Diabetes care. 2013

Bilateral adrenal incidentalomas: a case report and review of diagnostic challenges. 

Case reports in endocrinology. 2013

Challenges and future directions of the T1D Exchange Clinic Network and registry. 

Journal of Diabetes Science and Technology. 2013

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. 

American Heart Journal. 2013

Determining the influence of type 1 diabetes on two common eating disorder questionnaires. 

Diabetes Educator. 2013

Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry. 

Diabetes care. 2013

Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol). 

Endocrine Practice. 2013

Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. 

Diabetes care. 2013

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks. 

Diabetes, Obesity & Metabolism. 2013

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. 

Diabetes care. 2013

No racial differences in the association of glycated hemoglobin with kidney disease and cardiovascular outcomes. 

Diabetes care. 2013

Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). 

Diabetes Technology & Therapeutics. 2013

Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. 

Journal of Diabetes Science and Technology. 2013

Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. 

Journal of Clinical Endocrinology and Metabolism. 2013

Threshold-based insulin-pump interruption for reduction of hypoglycemia. 

New England Journal of Medicine. 2013

A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. 

Diabetes care. 2012

Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study. 

Diabetes Technology & Therapeutics. 2012

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. 

Diabetes care. 2012

Can a tool that automates insulin titration be a key to diabetes management?. 

Diabetes Technology & Therapeutics. 2012

Characteristics of persons with an eating disorder and type 1 diabetes and psychological comparisons with persons with an eating disorder and no diabetes. 

International Journal of Eating Disorders. 2012

Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. 

Pediatric Diabetes. 2012

Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. 

Cardiovascular Diabetology. 2012

Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). 

Diabetes Therapy. 2012

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 

Diabetologia. 2012

Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting. 

Diabetes, Obesity & Metabolism. 2012

Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. 

Diabetes care. 2012

Preadmission glycemic control and changes to diabetes mellitus treatment regimen after hospitalization. 

Endocrine Practice. 2012

The T1D Exchange clinic registry. 

Journal of Clinical Endocrinology and Metabolism. 2012

Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. 

Diabetes Technology & Therapeutics. 2011

Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. 

Diabetes Technology & Therapeutics. 2011

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. 

Diabetic Medicine. 2011

EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. 

American Heart Journal. 2011

Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. 

Current Medical Research and Opinion. 2011

Exenatide BID observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. 

Current Medical Research and Opinion. 2011

Feasibility of measuring gastric emptying time, with a wireless motility device, after subjects consume fiber-matched liquid and solid breakfasts. 

Appetite. 2011

Improving blood pressure control in individuals with diabetes: a quality improvement collaborative. 

Joint Commission journal on quality and patient safety. 2011

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. 

Diabetologia. 2011

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. 

Archives of Internal Medicine. 2011

Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. 

Diabetes care. 2011

The Minnesota Diabetes Plan 2015: stemming the tide on an epidemic and improving patient care. 

Minnesota Medicine. 2011

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. 

Annals of Internal Medicine. 2011

Diabetes and cancer: a consensus report. 

CA: A Cancer Journal for Clinicians. 2010

Diabetes and cancer: a consensus report. 

Diabetes care. 2010

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. 

New England Journal of Medicine. 2010

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. 

American Journal of Medicine. 2010

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. 

Lancet (London, England). 2010

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. 

Diabetes care. 2010

Point: The reporting of estimated glucose with hemoglobin A1c. 

Clinical Chemistry. 2010

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. 

BMJ (Clinical research ed.). 2010

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. 

BMJ (Clinical research ed.). 2010

A1C predicts type 2 diabetes and impaired glucose tolerance in a population at risk: the community diabetes prevention project. 

Diabetology & Metabolic Syndrome. 2009

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. 

Diabetes, Obesity & Metabolism. 2009

Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System. 

Diabetes Technology & Therapeutics. 2009

Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. 

Endocrine Practice. 2009

Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?. 

Diabetes Technology & Therapeutics. 2009

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. 

Current Medical Research and Opinion. 2009

Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial. 

Surgery for Obesity and Related Diseases. 2009

Low cardiorespiratory fitness in people at risk for type 2 diabetes: early marker for insulin resistance. 

Diabetology & Metabolic Syndrome. 2009

Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. 

Diabetes care. 2008

Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. 

Diabetes Technology & Therapeutics. 2008

Consensus report of the coalition for clinical research-self-monitoring of blood glucose. 

Journal of Diabetes Science and Technology. 2008

Creatinine clearance and blood pressure: a 34-year circadian study. 

Clinica Terapeutica. 2008

Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. 

Current Medical Research and Opinion. 2008

Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. 

Diabetes care. 2008

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. 

Lancet (London, England). 2008

Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. 

American Journal of Cardiology. 2007

Treatment models from the International Diabetes Center: advancing from oral agents to insulin therapy in type 2 diabetes. 

Endocrine Practice. 2006

Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus. 

Coronary Artery Disease. 2005

Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. 

Diabetes care. 2005

Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. 

Diabetes care. 2005

Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control. 

Diabetes Technology & Therapeutics. 2005

Macrovascular risk factors in patients with diabetes: physician treatment strategies and extent of control. 

Endocrine Practice. 2005

Macrovascular risk factors in patients with diabetes: physician treatment strategies and extent of control. 

Endocrine Practice. 2005

Undetected, uncontrolled blood pressure in type 2 diabetes: self-monitored blood pressure profiles. 

Blood Pressure. 2004

Characterizing blood pressure control in individuals with Type 2 diabetes: the relationship between clinic and self-monitored blood pressure. 

Diabetic Medicine. 2003

Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. 

Diabetes care. 2003

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. 

JAMA. 2003

Use of an automated device for alternative site blood glucose monitoring. 

Diabetes care. 2001

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. 

Diabetes care. 2000

Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy. 

Diabetes Educator. 2000

Optimization of insulin therapy in patients with type 2 diabetes. 

Endocrine Practice. 2000

Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus. 

Journal of the American Dietetic Association. 1995

Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. 

Journal of the American Dietetic Association. 1995

A joint venture with the commonwealth of independent states. 

Diabetes care. 1993

Practice guidelines for nutrition care by dietetics practitioners for outpatients with non-insulin-dependent diabetes mellitus: methodologies for field-testing and cost-effectiveness analysis. 

Journal of the American Dietetic Association. 1992

Observations on C-peptide and free insulin in the blood during continuous subcutaneous insulin infusion and conventional insulin therapy. 

Diabetes. 1985

Observations on blood lipid and intermediary metabolite concentrations during conventional insulin treatment or CSII. 

Diabetes. 1985

Observations on control of glycemia with conventional insulin therapy or continuous subcutaneous insulin infusion. 

Diabetes. 1985

The Glucose Management Indicator: time to change course [editorial]?. 

Diabetes care.  47. 2024

Continuous glucose monitoring for type 2 diabetes: how does it compare with type 1 diabetes [editorial]?. 

Diabetes Technology & Therapeutics.  24. 2022

More green, less red: how color standardization may facilitate effective use of CGM data [editorial]. 

Journal of Diabetes Science and Technology.  16. 2022

Continuous glucose monitoring-derived data report-simply a better management tool [editorial]. 

Diabetes care.  43. 2020

Duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes [editorial]. 

Diabetes care.  43. 2020

Glucose management indicator (GMI): insights and validation using Guardian 3 and Navigator 2 sensor data [editorial]. 

Diabetes care.  42. 2019

Continuous glucose monitoring: transforming diabetes management step by step [editorial]. 

Lancet (London, England).  391. 2018

Evaluating interventions and titrations using fasting blood glucose [editorial]. 

Journal of Diabetes Science and Technology.  12. 2018

Identifying trends in undiagnosed diabetes in U.S. adults [editorial]. 

Annals of Internal Medicine.  168. 2018

Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels [editorial]. 

Annals of Internal Medicine.  168. 2018

Continuous glucose monitoring in patients with type 1 diabetes using insulin injections [editorial]. 

Diabetes care.  39. 2016

Trends in insulin use and diabetes control in the U.S.: 1988-1994 and 1999-2012 [editorial]. 

Diabetes care.  39. 2016

Threshold insulin-pump interruption to reduce hypoglycemia [editorial]. 

New England Journal of Medicine.  369. 2013

Integrated practice units are bridges, not 'archipelagoes' [editorial]. 

Health Affairs.  27. 2008

The insulin sliding scale is not dead [editorial]. 

Archives of Internal Medicine.  158. 1998

Diabetes technology in 2019 [invited speaker]

2019

Diabetes technology in clinical practice [invited speaker]

2018

The connection between dementia and diabetes [invited speaker]

2017

Diabetes technology: beyond insulin pumps [invited speaker]

2016

Autonomic neuropathy in type 1 diabetes (T1D): findings from the T1D Exchange [poster]

2019

CGM-based clinical targets: recommendations from the International Consensus on Time-in-Range (TIR) [poster]

2019

Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care [poster]

2019

Hybrid closed-loop in adults with type 1 diabetes: impact of baseline A1c on glucose outcomes and insulin delivery [poster]

2019

Low level of agreement in evaluation of continuous glucose monitoring profiles [poster]

2019

Optimal sampling duration of hybrid closed-loop therapy to determine long-term glycemic control in adults with type 1 diabetes [poster]

2019

Comparing patch vs.pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles [poster]

2018

Efficacy and safety of faster aspart compared with insulin aspart both with insulin degludec in adults with T1D [poster]

2018

Hypoglycaemia with mealtime fast-acting insulin aspart versis insulin aspart across two large type 1 diabetes trials [poster]

2018

Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy [poster]

2018

Improved glycemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes [poster]

2018

Incidence of diabetes and hyperglycemia among patients receiving glucocorticoids with chemotherapy [poster]

2018

Increased HbA1c variability may shorten time to microalbuminuria development in type 1 diabetes (T1D) [poster]

2018

Optimizing basal-bolus therapy in T2D—a randomized controlled trial comparing bolus insulin delivery using an insulin patch vs. an insulin pen [poster]

2018

Real-world improvement in above-target estimated A1c with sequential use of professional flash continuous glucose monitoring for individuals with diabetes [poster]

2018

Pivotal trial of a hybrid closed-loop system in type 1 diabetes (T1D) [poster]

2016

Reducing staff time with optimized work flows and standardized ambulatory glucose profile (AGP) [poster]

2015

Diagnosis and managment of type 2 diabetes mellitus in adults [health care guideline]

2009

Diagnosis and managment of type 2 diabetes mellitus in adults [health care guideline]

2008

Decreasing the burden of carbohydrate counting and meal announcement with automated insulin delivery, meal recognition, and autocorrection doses: a case study [review]. 

Diabetes Technology & Therapeutics. 2024

Effective strategies for the prevention and mitigation of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia: optimizing patient care [review]. 

Clinical Breast Cancer. 2024

Is it time to move beyond TIR to TITR? Real-world data from over 20,000 users of continuous glucose monitoring in patients with type 1 and type 2 diabetes [review]. 

Diabetes Technology & Therapeutics. 2024

Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme [review]. 

Diabetes, Obesity & Metabolism. 2024

Primary care and diabetes technologies and treatments [review]. 

Diabetes Technology & Therapeutics. 2024

Update on measuring ketones [review]. 

Journal of Diabetes Science and Technology. 2024

Using continuous glucose monitoring data in daily clinical practice [review]. 

Cleveland Clinic Journal of Medicine. 2024

Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association [review]. 

Diabetologia. 2023

Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from Diabetes Technology Society [review]. 

Progress in Cardiovascular Diseases. 2023

Continuous glucose monitoring and metrics for clinical trials: an international consensus statement [review]. 

The lancet. Diabetes & endocrinology. 2023

Coverage for continuous glucose monitoring for individuals with type 2 diabetes treated with nonintensive therapies: an evidence-based approach to policymaking [review]. 

Diabetes Technology & Therapeutics. 2023

Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator [review]. 

Diabetes Technology & Therapeutics. 2023

Prevalence, cost, and burden of diabetic ketoacidosis [review]. 

Diabetes Technology & Therapeutics. 2023

Primary care and diabetes technologies and treatments [review]. 

Diabetes Technology & Therapeutics. 2023

Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association [review]. 

Diabetes care. 2022

Continuous glucose monitoring in primary care - are we there [review]?. 

Current Opinion in Endocrinology, Diabetes, and Obesity. 2022

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis [meta-analysis]. 

BMJ open diabetes research & care. 2022

Primary care and diabetes technologies and treatments [review]. 

Diabetes Technology & Therapeutics. 2022

Comparison of second-generation basal insulin analogs: a review of the evidence from continuous glucose monitoring [review]. 

Diabetes Technology & Therapeutics. 2021

Primary care and diabetes technologies and treatments [review]. 

Diabetes Technology & Therapeutics. 2021

What's wrong with this picture? A critical review of current Centers for Medicare & Medicaid Services coverage criteria for continuous glucose monitoring [review]. 

Diabetes Technology & Therapeutics. 2021

Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group [review]. 

Diabetes care. 2020

HbA1c: the glucose management indicator, time in range, and standardization of continuous glucose monitoring reports in clinical practice [review]. 

Endocrinology and Metabolism Clinics of North America. 2020

The influence of diet interventions using whole, plant food on the gut microbiome: a narrative review [review]. 

Journal of the Academy of Nutrition and Dietetics. 2020

The role of blood glucose monitoring in diabetes management [review]

2020

Advanced technology in the management of diabetes: which comes first-continuous glucose monitor or insulin pump [review]?. 

Current Diabetes Reports. 2019

Advances in technology for management of type 1 diabetes [review]. 

Lancet (London, England). 2019

Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time-in-Range [review]. 

Diabetes care. 2019

Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice [review]. 

Diabetes Technology & Therapeutics. 2019

Approach to using trend arrows in the freestyle libre flash glucose monitoring systems in adults [review]. 

Journal of the Endocrine Society. 2018

Clinical use of continuous glucose monitoring in adults with type 2 diabetes [review]. 

Diabetes Technology & Therapeutics. 2017

Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group [review]. 

Diabetologia. 2017

Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group [review]. 

Diabetes care. 2017

International consensus on use of continuous glucose monitoring [review]. 

Diabetes care. 2017

Role of continuous glucose monitoring in clinical trials: recommendations on reporting [review]. 

Diabetes Technology & Therapeutics. 2017

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [review]. 

Diabetes care. 2012

The safety of incretin-based therapies--review of the scientific evidence [review]. 

Journal of Clinical Endocrinology and Metabolism. 2011

Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications [review]. 

American Journal of Medicine. 2010

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use [review]. 

European Journal of Internal Medicine. 2009

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use [review]. 

American Journal of Medicine. 2009

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association [review]. 

Journal of the American College of Cardiology. 2009

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [review]. 

Circulation. 2009

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [review]. 

Diabetes care. 2009

A new look at screening and diagnosing diabetes mellitus [review]. 

Journal of Clinical Endocrinology and Metabolism. 2008

Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM) [review]. 

Diabetes Technology & Therapeutics. 2008

The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference [review]. 

American Journal of Medicine. 2005

Comprehensive management of patients with type 2 diabetes: establishing priorities of care [review]. 

American Journal of Managed Care. 2001

Intensified diabetes management: lessons from the diabetes control and complications trial [review]. 

International Journal of Clinical Pharmacology and Therapeutics. 1995

Change in A1C with and without intermittent use of CGM in adults with type 2 diabetes participating in the Onduo Virtual Diabetes Clinic [abstract]. 

Diabetes. 2020

Cross-study comparisons done right: an illustration using two pivotal trials of closed-loop systems [abstract]. 

Diabetes. 2020

Derived time-in-range is associated with MACE in T2D: data from the DEVOTE Trial [abstract]. 

Diabetes. 2020

First home evaluation of the Omnipod Horizon automated glucose control system at specific glucose targets in children with type 1 diabetes [abstract]. 

Diabetes. 2020

Freestyle Libre system use is associated with reduction in inpatient and outpatient emergency acute diabetes events and all-cause hospitalizations in patients with type 2 diabetes [abstract]. 

Diabetes. 2020

Patient-reported outcomes for 2,335 adults with type 2 diabetes using the omnipod insulin management system show glycemic improvement over first 90 days of use [abstract]. 

Diabetes. 2020

Patients’ interpretation of Ambulatory Glucose Profile (AGP), CGM, and pump reports [abstract]. 

Diabetes. 2020

Safety and glycemic outcomes of the MiniMed advanced hybrid closed-loop (AHCL) system in subjects with T1D [abstract]. 

Diabetes. 2020

Ultra-Rapid Lispro (URLi) demonstrates similar time-in-target range to Humalog with the Medtronic MiniMed 670G Hybrid Closed-Loop System [abstract]. 

Diabetes. 2020

Utilization of continuous glucose monitors is associated with reduction in inpatient and outpatient emergency acute diabetes events regardless of prior blood test strip usage [abstract]. 

Diabetes. 2020

Alogliptin in triple therapy with metformin and sulfonylureas provides significant reductions in HbA1c and is well tolerated: an analysis from the EXAMINE Trial [abstract]. 

Diabetes. 2016

Double-blind mealtime faster-acting insulin aspart vs. insulin aspart in basal-bolus improves glycemic control in T1D: the Onset 1 Trial [abstract #293-OR]. 

Diabetes. 2016

Effect of empagliflozin on nephropathy in subgroups by age: results from EMPA-REG outcome [abstract 1198-P]. 

Diabetes. 2016

Efficacy and safety of LixiLan vs. insulin glargine according to baseline characteristics in patients with type 2 diabetes from the LixiLan-L Trial [abstract 1018-P]. 

Diabetes. 2016

Efficacy and safety of the insulin glargine plus lixisenatide fixed-ratio combination vs. insulin glargine in patients wth T2DM: the LixiLan-L trial [abstract]. 

Diabetes. 2016

Hypoglycemia is associated with increased risk of cardiovascular events: results from the EXAMINE Trial [abstract]. 

Diabetes. 2016

Mortality findings from the EXAMINE Trial [abstract]. 

Diabetes. 2016

Novel pattern identification through standardized data display using the ambulatory glucose profile (AGP) report [abstract]. 

Diabetes Technology & Therapeutics. 2016

Early response to liraglutide 3.0 mg in adults with overweight or obesity and type 2 diabetes: subanalysis of the SCALE Diabetes Trial [abstract]. 

Diabetes. 2015

Glucose variability in type 2 diabetes: the initial results of the FLAT-SUGAR trial [abstract 385-OR]. 

Diabetes. 2015

Glycemic variability correlated with 1.5-anhydroglucitol (1.5 AHG) but not with markers of oxidation, inflammation, and endothelial function: baseline characteristics of the CAROLINA CGM sub-study [abstract]. 

Diabetes. 2015

Hypoglycemia and glucose variability in older adults with type 1 diabetes (T1D) [abstract 408-P]. 

Diabetes. 2015

Major cardiovascular outcomes in the EXAMINE trial according to ACE inhibitor use [abstract]. 

Diabetes. 2015

Superior reduction of HbA1c in a double-blind, randomized study of basal insulin peglispro (BIL) vs. insulin glargine (GL) in patients (pts) with T1D: IMAGINE 3 [abstract]. 

Diabetes. 2015

Trends in diabetes control and insulin use in the U.S., 1998-2010 [abstract]. 

Diabetes. 2015

Understanding patient and clinician glucose reporting preferences in type 1 diabetes: Ambulatory Glucose Profile (AGP) [abstract]. 

Diabetologia. 2015

CGM use in type 2 diabetes

2018

Methods for treating patients with impaired awareness of hypoglycemia

2021

Treatment of hypoglycemia unawareness with intranasal insulin

2017

Will the surge in new diabetes devices improve patient outcomes?

2020